Type 1 diabetes is a form of diabetes in which immune-mediated destruction of pancreatic beta cells usually leads to severe or absolute insulin deficiency. Beta cells are located in the pancreatic islets and normally secrete insulin in response to rising blood glucose. When too few functioning beta cells remain, endogenous insulin production cannot adequately control glucose, so glucose accumulates in the bloodstream while cells that depend on insulin-mediated glucose uptake have reduced access to circulating fuel.
The condition can occur at any age, although it is frequently diagnosed in childhood or adolescence. It is fundamentally different from type 2 diabetes, which commonly begins with insulin resistance and progressive beta-cell dysfunction. Type 1 diabetes is not caused by eating sugar or by ordinary lifestyle choices, and current clinical guidance treats it as an autoimmune disease in most cases.
The immune process underlying type 1 diabetes can be detected through islet autoantibodies. Modern classification recognises that type 1 diabetes can develop through stages rather than appearing suddenly without a preceding biological process. Stage 1 involves multiple islet autoantibodies with normoglycaemia and no symptoms; stage 2 involves autoimmunity accompanied by dysglycaemia but still without overt symptomatic diabetes; stage 3 is clinically manifest diabetes with hyperglycaemia and typically symptoms.
Autoantibodies are markers of immune activity against pancreatic islet components rather than antibodies against insulin in every case. Genetic susceptibility contributes to disease risk, while environmental factors are believed to influence disease initiation or progression, although the exact causes remain incompletely understood. This staged model is particularly important in research and specialist screening because it demonstrates that clinically obvious diabetes can be preceded by detectable autoimmune disease.
Symptoms of newly developed type 1 diabetes often appear relatively quickly because insulin deficiency can become severe over a short period. Typical manifestations include marked thirst, frequent urination, fatigue, blurred vision and unexplained weight loss. Because glucose cannot be adequately utilised and remains in the circulation, the kidneys excrete more glucose once the renal threshold is exceeded, drawing additional water into urine and producing polyuria and dehydration. The resulting dehydration stimulates thirst.
Lack of insulin also promotes breakdown of fat, producing ketone bodies. If insulin deficiency is profound, ketones can accumulate and cause diabetic ketoacidosis, or DKA, a potentially life-threatening metabolic emergency characterised by hyperglycaemia or sometimes significant ketosis with metabolic acidosis, dehydration and symptoms such as nausea, vomiting, abdominal pain and rapid breathing. WHO notes that severe hyperglycaemia in type 1 diabetes may be accompanied by nausea, vomiting or rapid breathing.
Insulin is essential for survival in established type 1 diabetes because the underlying problem is a profound deficiency of the hormone required to regulate glucose and suppress uncontrolled fat breakdown and ketone production. Treatment therefore involves insulin replacement from diagnosis onward, rather than merely attempting to stimulate endogenous insulin secretion. Insulin can be administered using multiple daily injections or an insulin pump, with regimens selected according to individual circumstances.
Modern management often incorporates continuous glucose monitoring, carbohydrate counting and structured adjustment of insulin doses. The purpose is not simply to produce a low glucose number but to balance insulin delivery with meals, exercise, illness, hormones and other factors while minimising both hyperglycaemia and hypoglycaemia. The NHS describes insulin as the main treatment and recommends regular glucose monitoring, HbA1c assessment, education and recognition of hypo- and hyperglycaemia.
Glucose management in type 1 diabetes requires understanding the relationship between carbohydrate intake and insulin requirements. Carbohydrates are digested into glucose and other sugars, and their quantity and absorption rate influence post-meal glucose. People using intensive insulin therapy may calculate carbohydrate amounts and use insulin-to-carbohydrate ratios, correction factors and basal insulin requirements. Basal insulin is intended to cover background metabolic needs, while rapid-acting insulin is used around meals and for corrections.
Physical activity can increase insulin sensitivity and glucose uptake by skeletal muscle, sometimes causing hypoglycaemia during or after exercise, while illness and stress hormones can increase glucose and insulin requirements. These relationships mean that insulin doses cannot be treated as static numbers. Diabetes education therefore covers carbohydrate counting, exercise, illness management, alcohol, driving, hypoglycaemia and other practical situations.
Type 1 diabetes should be distinguished from latent autoimmune diabetes in adults and from type 2 diabetes, although the boundaries can be clinically complex. Some adults develop autoimmune beta-cell destruction slowly and may initially appear to have type 2 diabetes because insulin requirements are not immediately absolute. Conversely, some people with type 2 diabetes eventually become markedly insulin deficient and require insulin without having autoimmune type 1 disease.
Classification can therefore require assessment of clinical history, age at onset, rate of progression, body composition, autoantibodies and sometimes C-peptide, a marker of endogenous insulin secretion. The term “insulin-dependent diabetes”, historically used for type 1 diabetes, is now less useful because some people with type 2 diabetes also require insulin. Similarly, the old term “juvenile diabetes” is inaccurate because type 1 diabetes can begin in adulthood.
Acute and chronic complications of type 1 diabetes arise from both high and low glucose. Hyperglycaemia can contribute to long-term microvascular and macrovascular complications, while excessive insulin can produce hypoglycaemia. A severe hypo can impair cognition, cause seizures or unconsciousness and require urgent treatment. DKA is a particularly important acute complication of insulin deficiency and can develop when insulin is omitted or becomes insufficient during illness or other circumstances. Long-term management therefore requires more than glucose measurement alone.
The NHS recommends regular HbA1c monitoring, kidney and cardiovascular assessments, eye screening and foot checks, alongside education about hypoglycaemia, hyperglycaemia and sick-day rules. Maintaining glucose within an individually agreed target range reduces the likelihood of complications, although treatment must be individualised to avoid excessive hypoglycaemia.
Type 1 diabetes is currently a lifelong condition for people with established clinical disease, although research is investigating immune therapies, beta-cell replacement, transplantation, encapsulation and other approaches that could alter the disease course. Modern technologies have substantially changed management without eliminating the underlying requirement for insulin in established disease. Continuous glucose monitors provide frequent interstitial glucose measurements, while insulin pumps deliver programmed and user-directed insulin.
Hybrid closed-loop systems combine a continuous glucose monitor with an insulin pump and algorithmic dosing, and the NHS states that some people with type 1 diabetes may be offered such systems during pregnancy. These technologies can reduce treatment burden and improve glucose control for appropriate users, but they still require clinical oversight, device management and understanding of insulin physiology. The fundamental defining feature remains severe insulin deficiency caused by beta-cell destruction rather than the particular technology used to manage it.
